The estimated Net Worth of Kathrine O'brien is at least $886 mil dollars as of 11 November 2021. Ms. brien owns over 7,000 units of AMAG Pharmaceuticals stock worth over $616,775 and over the last 6 years she sold AMAG stock worth over $0. In addition, she makes $269,642 as Independent Director at AMAG Pharmaceuticals.
Sign up
Ms. Brien AMAG stock SEC Form 4 insiders trading
Kathrine has made over 1 trades of the AMAG Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 7,000 units of AMAG stock worth $102,480 on 11 November 2021.
The largest trade she's ever made was buying 7,000 units of AMAG Pharmaceuticals stock on 11 November 2021 worth over $102,480. On average, Kathrine trades about 538 units every 0 days since 2018. As of 11 November 2021 she still owns at least 24,671 units of AMAG Pharmaceuticals stock.
You can see the complete history of Ms. brien stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kathrine O'Brien biography
Kathrine O'Brien serves as Independent Director of the Company. Ms. O'Brien served from 1984 to September 2018 in roles of increasing responsibility at Unilever PLC., a public consumer goods company. Most recently at Unilever, she served as Vice President/General Manager, Skin & Marketing Services and was a member of the North America Leadership Team. She has been a member of the Board of Directors of Tabula Rasa HealthCare, Inc., a public healthcare technology company, since November 2018 and has been a member of the Board of Trustees of Lehigh Valley Health Network, a medical group, since June 2017. Ms. O'Brien holds a B.A. in economics from Boston College and an M.B.A. from Columbia University. The Board believes that Ms. O'Brien's qualifications to sit on our Board include her decades of experience and recognition in the marketing field, including digital and social media, with a focus on women's personal care products, in light of our commercial programs, which focus, in part, in the women's health area and utilize direct-to-consumer marketing strategies.
What is the salary of Kathrine Brien?
As the Independent Director of AMAG Pharmaceuticals, the total compensation of Kathrine Brien at AMAG Pharmaceuticals is $269,642. There are 3 executives at AMAG Pharmaceuticals getting paid more, with Joseph Vittiglio having the highest compensation of $1,411,860.
How old is Kathrine Brien?
Kathrine Brien is 57, she's been the Independent Director of AMAG Pharmaceuticals since 2019. There are 6 older and 6 younger executives at AMAG Pharmaceuticals. The oldest executive at AMAG Pharmaceuticals, Inc. is Davey Scoon, 73, who is the Independent Director.
What's Kathrine Brien's mailing address?
Kathrine's mailing address filed with the SEC is 228 STRAWBRIDGE DRIVE, SUITE 100, MOORESTOWN, NJ, 08057.
Insiders trading at AMAG Pharmaceuticals
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C.... y Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
What does AMAG Pharmaceuticals do?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
What does AMAG Pharmaceuticals's logo look like?
Complete history of Ms. brien stock trades at AMAG Pharmaceuticals y Tabula Rasa HealthCare Inc
AMAG Pharmaceuticals executives and stock owners
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Joseph Vittiglio,
Executive Vice President, General Counsel, Corporate Secretary, Chief Business Officer -
Anthony Casciano,
Chief Operating Officer, Executive Vice President and Chief Commercial Officer -
Gino Santini,
Independent Chairman of the Board -
Kathrine O'Brien,
Independent Director -
Anne Phillips,
Independent Director -
Davey Scoon,
Independent Director -
John Fallon,
Independent Director -
James Sulat,
Independent Director -
David Johnson,
Independent Director -
Paul Fonteyne,
Independent Director -
Linda Lennox,
Vice President - Investor Relations and Corporate Communications -
Nancy Griffith,
Vice President - Scientific Communications And Medical Operations -
Kelly Schick,
Chief Human Resource Officer, Senior Vice President -
Brian Piekos,
Chief Financial Officer -
Scott Myers,
President, Chief Executive Officer, Director -
Barbara Deptula,
Director -
Brian P Kelley,
Director -
Lesley Russell,
Director -
Robert J Perez,
Director -
Edward H Myles,
COO & CFO -
William K Heiden,
President & CEO -
Nicholas Grund,
Chief Commercial Officer -
Elizabeth Scott Bolgiano,
Chief Human Resources Officer -
Partners Lp Caligan,
10% owner -
Julie Krop,
Chief Medical Officer -
James Alan Butcher,
EVP, Chief Business Officer -
Capital Management Lp Camber,
-
Capital, Llc Armistice Capi...,
-
Kenneth H Wilson,
SVP, Sales and Marketing -
Geoffrey Crouse,
EVP -
Edward P. Jordan,
SVP, Sales and Marketing -
Scott B Townsend,
SVP, General Counsel -
Capital Partners Gp, L.L.C....,
-
Steven Caffe,
SVP, Ch. Dev. and Reg. Officer -
Ron Zwanziger,
Director -
Michael Narachi,
Director -
Sheldon L Bloch,
Director -
Christopher G White,
Chief Business Officer and SVP -
Jerome M Lewis,
VP of Scientific Operations -
David Arkowitz,
CFO & Chief Business Officer -
Jerome Goldstein,
CEO and Treasurer -
Ricardo Zayas,
Sr. Vice President, Operations -
Mark B Skaletsky,
Director -
Silva Rajiv De,
Director -
Gary J Zieziula,
EVP, Chief Commercial Officer -
Michael D Loberg,
Director -
Frank E Thomas,
President & COO -
Michael N Avallone,
VP-Finance and CFO -
Scott A Holmes,
Chief Accounting Officer -
Joseph Vincent Bonventre,
Director -
Brian Jg Pereira,
President and CEO -
Greg Madison,
EVP, Chief Commercial Officer -
Theodore I Steinman,
Director -
Edward B Roberts,
Director -
Timothy G Healey,
SVP-Commercial Operations -
Lee F Md Ph D Allen,
CMO & SVP Clinical Dev. -
Joseph L Farmer,
Gen Counsel & VP Legal Affairs -
Louis Md Brenner,
Senior Vice President